12:00 AM
Oct 01, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Claudin 5 (CLDN5); occludin (OCLN); β amyloid (Aβ)


INDICATION: Alzheimer's disease (AD)

In vitro and mouse studies suggest inhibiting CLDN5 and OCLN could help treat AD. In endothelial cell cultures, knockdown of both CLDN5 and OCLN...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >